About PCSO-524
PCSO-524 (marketed as Lyprinol and OmegaXL) is a stabilised lipid fraction of the New Zealand green lipped mussel, supplying omega-3s including eicosatetraenoic acid (ETA), which inhibits both COX and LOX pathways. Human trials are small: a placebo-controlled asthma trial (Mickleborough et al. 2013, n=46) and a crossover trial (n=20) showed reduced airway inflammation and bronchoconstriction, and a randomised osteoarthritis trial benchmarked against fish oil reported pain relief but had no placebo arm. Brien et al. (2008) systematically reviewed Perna canaliculus preparations including the lipid extract and found consistent anti-inflammatory effects across small studies. Held as a separate entry from whole green lipped mussel extract because the clinical dose differs by an order of magnitude. Contraindicated in shellfish allergy.
What PCSO-524 supports
- Reduced airway inflammation and bronchoconstriction in small asthma RCTs
- Anti-inflammatory via dual COX/LOX inhibition from the omega-3 ETA
How much PCSO-524 to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
100–300
mg
Lipid (non-polar) extract of Perna canaliculus, dosed at 100–300 mg/day — roughly 10–20x more concentrated than whole or freeze-dried mussel powder (600–1500 mg/day), so the two must not be scored on the same scale. Asthma RCTs used 200 mg/day (4 × 50 mg capsules); joint trials used 100–200 mg/day.
Clinical evidence
Moderate clinical evidence. Small RCTs only (n=20–46) plus one osteoarthritis trial with no placebo arm; the manufacturer was involved in most studies. Directionally consistent, but not confirmed at scale.
Examine.com